• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cellebrite DI Ltd.

    3/21/24 9:10:31 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology
    Get the next $CLBT alert in real time by email
    S-8 1 ea0202191-s8_cellebrite.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on March 21, 2024

    Registration No. 333-        

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

    Cellebrite DI Ltd.

    (Exact name of registrant as specified in its charter)

     

    State of Israel

     

    Not Applicable

    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)
         

    94 Shlomo Shmelzer Road
    Petah Tikva 4970602, Israel

     

    Not Applicable

    (Address of Principal Executive Offices)   (Zip Code)

     

    Cellebrite DI Ltd.
    2021 Share Incentive Plan


    Cellebrite DI Ltd.
    2021 Employee Share Purchase Plan
    (Full title of the plan)


    Cellebrite, Inc.
    795 Franklin Ave #4
    Franklin Lakes, New Jersey 07417
    (Name and address of agent for service)


    (201) 848-8552
    (Telephone number, including area code, of agent for service)

     

    Copies to: 

     

    Colin J. Diamond
    Paul Hastings LLP
    200 Park Avenue
    New York, New York 10166
    Tel: (212) 318-6068
     

    David S. Glatt

    Elad Ziv
    Meitar | Law Offices
    16 Abba Hillel Road
    Ramat Gan, 5250608, Israel
    Tel: +972 (3) 610-3100

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐ Accelerated filer ☒
    Non-accelerated filer ☐ Smaller reporting company ☐
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Pursuant to General Instruction E of Form S-8, Cellebrite DI Ltd. (the “Registrant” or the “Company”) is filing this Registration Statement with the Securities and Exchange Commission (the “SEC”) to register (i) 9,578,572 additional ordinary shares, par value NIS 0.00001 per share (“Ordinary Shares”), of the Registrant reserved for issuance under the Cellebrite DI Ltd. 2021 Share Incentive Plan (the “2021 Plan”) resulting from automatic annual increases as of January 1, 2023 and January 1, 2024 and (ii) 1,154,677 additional Ordinary Shares reserved for issuance under the Cellebrite DI Ltd. 2021 Employee Share Purchase Plan (the “ESPP”) resulting from automatic annual increases as of January 1, 2023 and January 1, 2024. This Registration Statement hereby incorporates by reference the contents of the Registrant’s Registration Statement on Form S-8 filed with the SEC on November 8, 2021 (File No. 333-260878).

     

     

     

     

    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the SEC.

     

    1

     

     

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The Company hereby incorporates by reference in this Registration Statement the following:

     

    ●the Company’s annual report on Form 20-F (File No. 001-40772) for the fiscal year ended December 31, 2023, filed with the SEC on March 21, 2024 pursuant to Section 13(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”);

     

    ●all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act by the Company, including the Company’s reports on Form 6-K and amendments to Form 6-K, filed with the SEC on February 15, 2024 and March 6, 2024; and

     

    ●the description of the Company’s Ordinary Shares contained in the Company’s Registration Statement on Form 8-A, filed with the SEC on August 30, 2021, and any other amendment or report filed for the purpose of updating such description.

     

    All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, and, to the extent specifically designated therein, reports of foreign private issuer on Form 6-K furnished by the Company to the SEC, in each case, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing or furnishing of such documents.

     

    Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Notwithstanding the foregoing, no information is incorporated by reference in this Registration Statement where such information under applicable forms and regulations of the SEC is not deemed to be “filed” under Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, unless the report or filing containing such information indicates that the information therein is to be considered “filed” under the Exchange Act or is to be incorporated by reference in this Registration Statement.

     

    II-1

     

     

    Item 8. Exhibits.

     

    Exhibit Number   Description of Documents
    4.1   Amended and Restated Articles of Cellebrite DI Ltd. (as currently in effect) incorporated by reference to Exhibit 1.1 to the Company’s Annual Report on Form 20-F (File No. 001-40772) filed with the SEC on April 27, 2023.
    4.2   Specimen Ordinary Share Certificate of Cellebrite DI Ltd., incorporated by reference to Exhibit 4.5 to the Company’s Registration Statement on Form F-4 (File No. 333-256177), as amended, filed with the SEC on May 17, 2021.
    4.3   Cellebrite DI Ltd. 2021 Share Incentive Plan, incorporated by reference to Exhibit 10.11 to the Company’s Registration Statement on Form F-4 (File No. 333-256177), as amended, filed with the SEC on May 17, 2021.
    4.4   Cellebrite DI Ltd. 2021 Employee Stock Purchase Plan, incorporated by reference to Exhibit 10.12 to the Company’s Registration Statement on Form F-4 (File No. 333-256177), as amended, filed with the SEC on May 17, 2021.
    5.1   Opinion of Meitar | Law Offices with respect to the legality of the Ordinary Shares.
    23.1   Consent of Somekh Chaikin, a member firm of KPMG International.
    23.2   Consent of Korst Forer Gabbay & Kasierer, a member of EY Global.
    23.3   Consent of Meitar | Law Offices (included in Exhibit 5.1 to this Registration Statement).
    24.1   Power of Attorney of certain officers and directors (included on the signature page to this Registration Statement).
    107   Filing Fee Table.

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Petah Tikva, State of Israel, on the 21st day of March, 2024.

     

      CELLEBRITE DI LTD.
       
      By: /s/ Yossi Carmil
      Name:  Yossi Carmil
      Title: Chief Executive Officer and Director

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned constitutes and appoints each of Yossi Carmil and Dana Gerner, each acting alone, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement on Form S-8 and all post-effective amendments thereto, of Cellebrite DI Ltd., and to file the same, with all exhibits thereto, and other document in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that any such attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title of Capacities

     

    Date

             

    /s/ Yossi Carmil

      Chief Executive Officer and Director  

    March 21, 2024

    Yossi Carmil   (Principal Executive Officer)    
             

    /s/ Dana Gerner

      Chief Financial Officer  

    March 21, 2024

    Dana Gerner   (Principal Financial Officer and Principal Accounting Officer)    
             

    /s/ Thomas E. Hogan

      Chairman  

    March 21, 2024

    Thomas E. Hogan        
             

    /s/ Nadine Baudot-Trajtenberg

      Director  

    March 21, 2024

    Nadine Baudot-Trajtenberg

           
             
    /s/ Adam Clammer   Director   March 21, 2024
    Adam Clammer        
             

    /s/ Yonatan Domnitz

      Director  

    March 21, 2024

    Yonatan Domnitz        
             
    /s/ Dafna Gruber   Director   March 21, 2024
    Dafna Gruber        
             

    /s/ Elly Keinan

      Director  

    March 21, 2024

    Elly Keinan        
             

    /s/ Ryusuke Utsumi

      Director  

    March 21, 2024

    Ryusuke Utsumi

           
             

    /s/ Brandon Van Buren

      Director  

    March 21, 2024

    Brandon Van Buren

           

     

    II-3

     

     

    AUTHORIZED REPRESENTATIVE

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Cellebrite DI Ltd. has signed this registration statement on March 21, 2024.

     

      CELLEBRITE, INC.
       
      By: /s/ Yossi Carmil
      Name:  Yossi Carmil
      Title: Director

     

    II-4

     

    Get the next $CLBT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLBT

    DatePrice TargetRatingAnalyst
    3/28/2024$13.00 → $13.50Buy
    Needham
    3/13/2024Mkt Perform → Outperform
    William Blair
    2/16/2024$9.00 → $12.00Neutral → Buy
    BofA Securities
    7/19/2023$11.00Buy
    Craig Hallum
    8/12/2022$6.50 → $6.00Buy → Neutral
    BofA Securities
    8/12/2022Outperform → Mkt Perform
    William Blair
    2/24/2022$10.50Overweight
    JP Morgan
    2/11/2022$10.50Buy
    Deutsche Bank
    More analyst ratings

    $CLBT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on Cellebrite DI with a new price target

    Needham reiterated coverage of Cellebrite DI with a rating of Buy and set a new price target of $13.50 from $13.00 previously

    3/28/24 8:25:08 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite DI upgraded by William Blair

    William Blair upgraded Cellebrite DI from Mkt Perform to Outperform

    3/13/24 7:29:30 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite DI upgraded by BofA Securities with a new price target

    BofA Securities upgraded Cellebrite DI from Neutral to Buy and set a new price target of $12.00 from $9.00 previously

    2/16/24 7:23:02 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    $CLBT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cellebrite's 2026 Industry Trends Report Reveals Smartphones as the Leading Source of Digital Evidence in Investigations at 97%

    97% cite smartphones as top evidence source, up 24 points from 202495% agree digital evidence increases solvability, yet 94% say complexity strains caseloads65% believe AI can accelerate investigations, but one-third say policies prevent its useCloud receptiveness hit 42%, yet two-thirds still rely on physical mediaTYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 5, 2026 /PRNewswire/ -- Cellebrite (NASDAQ:CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today unveiled its 2026 Industry Trends Report, which surveyed 1,200 practitioners across 63 countries, marking the company's seventh annual report on how organizations

    2/5/26 8:30:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite to Report Fourth-Quarter and Fiscal Year 2025 Financial Results on February 11, 2026

    TYSONS CORNER, Va. and PETAH TIKVA, Israel, Jan. 21, 2026 /PRNewswire/ -- Cellebrite (NASDAQ:CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced it will report its fourth-quarter and fiscal year 2025 financial results before the U.S. markets open on Wednesday, February 11, 2026. Later that same morning, Cellebrite will host a live conference call and webcast to review the Company's financial results for the fourth quarter of 2025 and discuss its 2026 outlook. Relevant details include: Date: Wednesday, February 1

    1/21/26 9:00:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite Completes Acquisition of Corellium, Extending the Industry's Most Advanced AI-Powered Digital Investigation Platform

    TYSONS CORNER, Va. and PETAH TIKVA, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ:CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced it has substantially expanded its capabilities through the acquisition of Corellium, a leader in Arm-based virtualization software. The addition of Corellium's technology and world-class technical talent further strengthens Cellebrite's market and technology leadership. This combination creates the industry's most complete digital investigation portfolio spanning physical device access, virtual device testing and real-time intelligence. The technology enable

    12/2/25 8:00:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    $CLBT
    SEC Filings

    View All

    SEC Form 6-K filed by Cellebrite DI Ltd.

    6-K - Cellebrite DI Ltd. (0001854587) (Filer)

    12/2/25 8:15:02 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    SEC Form 144 filed by Cellebrite DI Ltd.

    144 - Cellebrite DI Ltd. (0001854587) (Subject)

    11/24/25 4:31:32 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    SEC Form 144 filed by Cellebrite DI Ltd.

    144 - Cellebrite DI Ltd. (0001854587) (Subject)

    11/21/25 4:13:18 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    $CLBT
    Leadership Updates

    Live Leadership Updates

    View All

    Cellebrite Appoints Holly Windham as General Counsel and Chief Compliance Officer

    TYSONS CORNER, Va. and PETAH TIKVA, Israel, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd (NASDAQ:CLBT), global leader in premier Digital Investigative and Intelligence solutions for the public and private sectors, today announced the appointment of Holly Windham as General Counsel and Chief Compliance Officer. Ms. Windham brings extensive legal leadership experience for growth-oriented technology companies with deep expertise spanning software, cloud platforms, cybersecurity, data privacy and public sector contracting – areas critical to Cellebrite's continued growth and market leadership. She will partner closely with Cellebrite's leadership team, overseeing all legal and complianc

    10/30/25 8:30:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite to Acquire Corellium

    TYSONS CORNER, Va. and PETAH TIKVA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ:CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced its agreement to acquire Corellium, a leader in Arm-based virtualization software. This combination will set a new standard for digital investigations and the security of smart devices including iOS, Android, automotive systems and any Arm-based IoT device. Customers across public safety, defense, intelligence and private sectors will benefit from: Accelerated identification of mobile vulnerabilities and exploitsIndustry-first ability to visualize and interact with virtual dev

    6/5/25 7:30:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite Appoints Michael D. Capellas to Board of Directors as Lead Independent Director

    TYSONS CORNER, Va. and PETAH TIKVA, Israel, Jan. 06, 2025 (GLOBE NEWSWIRE) --  Cellebrite (NASDAQ:CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced a series of Board updates to support the Company's continued growth into 2025 and beyond. As previously detailed on November 6, 2024, Thomas E. Hogan has been appointed interim CEO to begin 2025 as part of a planned leadership transition. In conjunction with stepping into this position, Mr. Hogan remains on the Company's Board of Directors and plans to revert to his position as chairman upon the eventual appointment of a new CEO. As part of Cellebrite's ongoing commitment to

    1/6/25 8:00:00 AM ET
    $CLBT
    $CSCO
    Computer Software: Prepackaged Software
    Technology
    Computer Communications Equipment
    Telecommunications

    $CLBT
    Financials

    Live finance-specific insights

    View All

    Cellebrite to Report Fourth-Quarter and Fiscal Year 2025 Financial Results on February 11, 2026

    TYSONS CORNER, Va. and PETAH TIKVA, Israel, Jan. 21, 2026 /PRNewswire/ -- Cellebrite (NASDAQ:CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced it will report its fourth-quarter and fiscal year 2025 financial results before the U.S. markets open on Wednesday, February 11, 2026. Later that same morning, Cellebrite will host a live conference call and webcast to review the Company's financial results for the fourth quarter of 2025 and discuss its 2026 outlook. Relevant details include: Date: Wednesday, February 1

    1/21/26 9:00:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite Announces Third-Quarter 2025 Results

    ARR grew 19% to $439.8 million; Revenue grew 18% to $126.0 million Net income of $20.2 million supports non-GAAP net income of $36.9 million and adjusted EBITDA of $37.7 million, 29.9% adjusted EBITDA margin TYSONS CORNER, Va. and PETAH TIKVA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ:CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced financial results for the three and nine months ending September 30, 2025. "Cellebrite once again delivered a balanced and solid performance," stated Thomas E. Hogan, Cellebrite's CEO. "We exceeded the high end of our prior adjusted EBITDA guidance with revenue at the hi

    11/12/25 4:01:00 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite to Report Third-Quarter 2025 Financial Results on November 12, 2025

    TYSONS CORNER, Va. and PETAH TIKVA, Israel, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ:CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced it will report its third-quarter 2025 financial results after the U.S. market close on Wednesday, November 12, 2025. Later that same day, Cellebrite will host a live conference call and webcast to review the Company's financial results for the third quarter of 2025 and discuss its full-year 2025 outlook. Relevant details include: Date:Wednesday, November 12, 2025Time:5:00 p.m. ETCall-In Number:203-518-9814 / 800-274-8461Conference ID:CLBTQ325Event URL:https://investors.cellebri

    10/17/25 9:00:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    $CLBT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Cellebrite DI Ltd.

    SC 13D/A - Cellebrite DI Ltd. (0001854587) (Subject)

    9/17/24 4:33:52 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by Cellebrite DI Ltd.

    SC 13D/A - Cellebrite DI Ltd. (0001854587) (Subject)

    8/29/24 6:07:01 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Cellebrite DI Ltd. (Amendment)

    SC 13G/A - Cellebrite DI Ltd. (0001854587) (Subject)

    3/12/24 12:38:56 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology